Mice bearing human NSCLC EBC-1 cells were treated with ASOs by s.c. injection at 50 mg/kg, five times a week for five weeks.
A) Accumulation of MALAT1 ASO in both tumor and tumor-associated stromal cells was demonstrated by IHC using an antibody specific for ASOs.
B) Human and mouse MALAT1 RNA levels in EBC-1 tumor were measured by qRT-PCR using species-specific probe/primer sets and verified the downregulation of MALAT1 in human tumor and murine normal tissue after ASO application in vivo in the animal model.
C) Reduction in MALAT1 RNA levels in both tumor and its surrounding stromal cells was visualized by the ‘ViewRNA’ ISH method using species-specific probes.